Data at ADA 2026 Highlights Key Findings from Clinical and Real‑World Studies of Afrezza® (Inhaled Insulin) Across Pediatric Care, Pregnancy, and AID Use
New UK economic analyses show improved patient outcomes and health system savings – including nearly £200 million in projected UK NHS savings over 5 years – through increased uptake of home-based peritoneal dialysis compared to in-center hemodialysis
MannKind Enters Data-Rich Development Period with Completion of Randomization in Phase 1b INFLO-1 Study and Enrollment of First Patient in Phase 2 INFLO-2
First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...
First-of-its-kind strip technology delivers full-mouth coverage and outperforms one of the most widely used dental supplements in head-to-head company sponsored clinical testingDUBOIS, Pa., June...
Charity auction raises $250,000 for Children's Miracle Network Hospitals
NEW YORK, Aug. 12, 2025 /PRNewswire/ -- Children's Miracle Network Hospitals (CMN Hospitals) announced that...
NEW YORK, Aug. 09, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Unicycive Therapeutics, Inc. (“Unicycive” or the “Company”) (NASDAQ: UNCY). Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.
CAMBRIDGE, Mass., Aug. 01, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted four newly-hired employees options to purchase an aggregate of 238,500 shares of Akebia’s common stock on July 31, 2025. The options were granted as an inducement material to each employee entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4).
CANSCAN study enrolled 120 patients with chronic kidney disease using the investigational, semi-autonomous VxWave™ Ultrasound Imaging SystemThe VxWave Ultrasound Imaging System potentially provides important insights...
Value-based kidney care leader expands capabilities in CHF care management, commercial self-insured populations, and AI-driven disease identification and payment integrity services
MCLEAN, Va., July 22,...